Research programme - kinase-inhibiting RNase attenuators - OptiKira

Drug Profile

Research programme - kinase-inhibiting RNase attenuators - OptiKira

Alternative Names: Cell death inhibitors - OptiKira; ERN1 protein inhibitors - OptiKira; Small molecule therapeutics - OptiKira

Latest Information Update: 06 Feb 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator OptiKira
  • Class Small molecules
  • Mechanism of Action Cell death inhibitors; ERN1 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Diabetes mellitus; Retinitis pigmentosa
  • Research Amyotrophic lateral sclerosis

Most Recent Events

  • 02 Feb 2015 OptiKira licenses technology from University of California at San Francisco and the University of Washington
  • 02 Feb 2015 OptiKira has patents for kinase-inhibiting RNase attenuators in USA
  • 02 Feb 2015 Early research in Amyotrophic lateral sclerosis in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top